Willow Biosciences Inc. Stock Canadian Securities Exchange
Equities
WLLW
CA97111B4047
Pharmaceuticals
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CAD | -.--% | -.--% | -.--% |
Apr. 01 | Willow Biosciences Narrows 2023 Loss YOY | MT |
Mar. 29 | Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | 821K 601K | Sales 2023 | 1.17M 858K | Capitalization | 12.42M 9.1M |
---|---|---|---|---|---|
Net income 2022 | -14M -10.25M | Net income 2023 | -13M -9.52M | EV / Sales 2022 | -0.95 x |
Net cash position 2022 | 15.01M 10.99M | Net cash position 2023 | 1.63M 1.19M | EV / Sales 2023 | 9.21 x |
P/E ratio 2022 |
-0.96
x | P/E ratio 2023 |
-0.95
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.66% |
Managers | Title | Age | Since |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 19-04-11 |
Travis Doupe
DFI | Director of Finance/CFO | - | 19-04-11 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 19-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 23-02-20 |
Donald Archibald
BRD | Director/Board Member | 63 | 19-04-11 |
Director/Board Member | 51 | 19-04-11 |
1st Jan change | Capi. | |
---|---|---|
-4.63% | 87.31B | |
+2.63% | 40.86B | |
-21.76% | 29.36B | |
+58.56% | 24.49B | |
-14.78% | 17.31B | |
-18.49% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |
- Stock Market
- Equities
- WLLW Stock
- WLLW Stock